Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.57 |
| ▸ | ITGAV | P06756 | 10/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.53 |
| ▸ | MC4R | P32245 | 7/20 | 0.49 |
| ▸ | MC5R | P33032 | 7/20 | 0.49 |
| ▸ | MC3R | P41968 | 7/20 | 0.49 |
| ▸ | MC1R | Q01726 | 7/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21907003 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL21906964 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL19365167 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL16359838 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL13299963 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL19365171 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL19372512 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL16508340 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL19365170 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL19102249 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870664-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2020-12-22 | — | — | US | disclosed |
| US-20190225625-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870664-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | NCL, NUDC, C3AR1 | ITGB3 516/4885ITGAV 814/4885ITGA5 571/4885 |
| US-20190225625-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | ITGB3 516/4885ITGAV 814/4885ITGA5 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.